Cadila Pharmaceuticals Sweden AB is a wholly-owned subsidiary of Cadila Pharmaceuticals Limited, India.
Over the last six decades, the company has been developing, manufacturing and selling pharmaceutical products in over eighty-five countries around the World.
Our product basket includes branded and generic formulations covering more than 45 therapeutic segments, biotechnology products, plant tissue culture and more than 38 APIs and intermediates. In the services realm, our offering includes Pre-Clinical and Clinical Research as well as Contract Manufacturing.
We have scientific collaborations with leading Swedish companies for preventing in-patient infections and development of novel treatment for specific and acute infections, for developing Antibiotic Resistant Breakers and innovative treatment in inflammation and pain management.
The Swedish office has been set up to ensure success of ongoing and future collaborations between Swedish companies and institutions, and our Indian organization. We encourage regional researchers and companies to get in touch with us to discuss potential collaborations or our service offerings.
MediGelium provides services within the specialist fields of pharmaceutical formulation development and applied surface and colloid chemistry. The company’s expertise is particularly related to liquid and semisolid formulations for topical, oral, and/or parenteral use. Many new drug compounds have low or insignificant solubility in water and/or have unacceptably low bioavailability. MediGelium has long experience of using polar lipids and other surface active substances in pharmaceutical formulations, such as oil-in-water emulsions, liposomes, and self-emulsifying oily liquids, formulations that may overcome the solubility and bioavailability problems of the incorporated drug compounds. The company also has long experience of filing new patent applications within the field of liquid and semisolid pharmaceutical formulations.
Lipidor AB is a drug delivery company focusing on topical treatment. Its proprietary AKVANO® technology can accommodate most drug substances used for topical treatment in its novel sprayable dosage form. The lead product concept is a sprayable AKVANO®-based product concept with calcipotriol being developed for psoriasis vulgaris. The company is also evaluating a similar AKVANO®-based product concept with a combination of calcipotriol and a corticosteroid for the same indication.
Inhalation Sciences Sweden AB is a Contract Research Organization Supporting Enhanced Preclinical and Clinical Research in Early Drug Development.
The company is developing a new patented development path for inhalation drugs and inhaler devices that will lead to efficient aerosol therapies.
The business concept is based on creating early predictive preclinical and clinical pharmacokinetics while staying in control of dosing and mass balance throughout the development process, using only minute amounts of a compound.
The development path extends from discovery to early clinical trials.
It is envisaged that this new process of precision dosing will reduce late stage product attritions and significantly cut costs, timelines, and improve the productivity in respiratory drug development.